Emerging Cancer Treatments and Ticket Pricing Controversies

3min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

This chapter delves into promising new cancer therapies, especially for younger patients, with a focus on pancreatic and colorectal cancers. It also addresses the debate over Ticketmaster's pricing strategies and the UK government's scrutiny of dynamic pricing practices.

The UK blocks some arms shipments to Israel, audit firms are fighting against new oversight rules in the US, and the same technology that brought us Covid-19 vaccines could also be used to fight cancer. Plus, the Oasis revival tour is so popular it triggered a UK investigation into Ticketmaster.

Mentioned in this podcast:

UK to halt exports of some arms to Israel citing possible law breaches External Link

The Covid-era tech that could reinvent cancer care

Accountancy firms fight back against audit reforms

UK government to probe ‘dynamic’ pricing behind Oasis ticket price surge

The FT News Briefing is produced by Niamh Rowe, Fiona Symon, Sonja Hutson, Kasia Broussalian and Marc Filippino. Additional help from Michela Tindera, Breen Turner, Sam Giovinco, Peter Barber, Michael Lello, David da Silva and Gavin Kallmann. Our engineer is Monica Lopez. Topher Forhecz is the FT’s executive producer. The FT’s global head of audio is Cheryl Brumley. The show’s theme song is by Metaphor Music.

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.